Annex Table 1.
Declaration of Conflict of Interests
The members of the guideline development/ adaptation group and the external review group have no academic, financial, or competing interests to declare and none of them were involved in the development of the original source guideline(s).
Any identified potential COI has been reported below.
|
Egyptian Pediatric Clinical Practice Guidelines Committee (EPG) Guideline Development/ Adaptation Group (Clinicians subgroup) |
|||||
|
Name |
Affiliation, Area of expertise / Country / Primary location [work] |
Contribution |
|||
|
Prof. Suzan Samir Gad |
Pediatrics Department, Consultant, Suez Canal |
Clinical Chair, GAG |
|||
|
Prof. Ahmed Foad |
Alexandria |
Clinical Expert GAG Member |
|||
|
Prof. Ahmed Hamdy |
Ain Shams |
Clinical Expert GAG Member |
|||
|
Prof. Amal Mahfouz |
Alexandria |
Clinical Expert GAG Member |
|||
|
Prof. Ayman Emil Eskandr |
Cairo |
Clinical Expert GAG Member |
|||
|
Prof. Gihan Bebars |
Minia |
Clinical Expert GAG Member |
|||
|
Prof. Hala Hussien Mansour |
Cairo |
Clinical Expert GAG Member |
|||
|
prof. Maha Abou Zekri |
Cairo |
Clinical expert GAG Member |
|||
|
Prof. Mohamed Ezz |
Mansoura |
Clinical Expert GAG Member |
|||
|
Prof. Naglaa Abu Faddan |
Assuit |
Clinical Expert GAG Member |
|||
|
Prof. Hossam El Saadny |
|
Clinical Expert GAG Member |
|||
|
Egyptian Pediatric Clinical Practice Guidelines Committee (EPG) Guideline Development/ Adaptation Group (Guideline Methodologists subgroup) |
|||||
|
Name |
Affiliation, Area of expertise / Country / Primary location [work] |
Contribution |
|||
|
Prof. Ashraf Abdel Baky |
Professor of Pediatrics Ain Shams University, Egypt Founder and Chair of EPG |
Overseeing the adolopment process of the guidelines, training and education of new members, revision of the final draft, and organizing online meetings of GDG |
|||
|
Dr. Yasser Sami Amer |
1. Pediatrics Department and Clinical Practice Guidelines and Quality Research Unit, Quality Management Department, King Saud University Medical City, Riyadh, Saudi Arabia; 2. Research Chair for Evidence-Based Health Care and Knowledge Translation, King Saud University, Riyadh, Saudi Arabia; 3. Chair, Adaptation Working Group, Guidelines International Network (GIN), Perth, Scotland 4. Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil. |
Overseeing the adolopment process of the guidelines, training and education of new members, participating in writing up the methodology of adaptation process, guideline appraisal, and revision of the final draft |
|||
|
Dr. Nahla Gamaleldin |
Lecturer of pediatrics, Faculty of Medicine, Modern University for Technology and Information (MTI), Egypt |
Participating in multiple steps of the guideline adaptation process, Writing the methodology of adaptation process and revised the whole document. |
|||
|
External Reviewers Group (ERG) |
|||||
|
External Reviewer(s) for Clinical Content |
|||||
|
|||||
|
International Peer Reviewers |
|||||
|
External Reviewer(s) for methodology |
|||||
|
Prof. Iván D. Flórez |
Department of Pediatrics, University of Antioquia, Medellín, Colombia, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada, Leader, AGREE Collaboration (Appraisal of Guidelines for Research & Evaluation) Director, Cochrane Colombia |
||||
|
Prof. Airton Tetelbom Stein
|
Professor Titular de Saúde Coletiva, Fundação Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil Professor Adjunto, Universidade Luterana do Brasil (Ulbra), Canoas, Brazil Coordenador de Diretrizes Clínicas, Grupo Hospitalar Conceição, Porto Alegre, Brazil 4. Member, Board of Trustees, Guidelines International Network (G-I-N) |
||||
The following annexes can be added as a package of standalone supplementary documents.
Keywords: The MeSH terms for "Guideline for the diagnosis and treatment of functional constipation in infants and children
on PubMed are: functional, constipation, infants, young children, Hirschsprung disease
Appendix Table 2. AGREE II assessment results and the standardized domain scores for the one ESPGHAN and NASPGHAN: JPGN 2014 included CPG
|
CPGs AGREE II DOMAINS |
CPG1 |
|
D1: Scope & Purpose |
93% |
|
D2: Stakeholder Involvement |
82.5% |
|
D3: Rigour of Development |
83.7% |
|
D4: Clarity & Presentation |
90.5% |
|
D5: Applicability |
83.6% |
|
D6: Editorial Independence |
88% |
|
OA 1 |
80% |
|
OA 2 (Recommend for use) |
Yes (all) |
This table uses the AGREE II Domain Score Color codes (< 40% red; > 41 – 70% yellow; > 71 % green)
Based on the results of the AGREE II assessment, the GAG decided to adapt/ adopt all of the recommendations from the XXXXXXXXXXXXXXXXXX CPG.
Appendix Table 3. Currency survey of the CPG developer
|
1. Are you aware of any new evidence relevant to this CPG statement? Yes/ No |
|
2. Is there any new evidence to invalidate any of the recommendations comprising the CPG? Yes/ No |
|
3. Are there any plans to update the CPG in the near future? Yes/ No |
|
4. When the CPG was last updated? XX/XX/XXXX What is the citation for the latest version? See Reference XXXXXXXXXX |
Appendix Table 4. Decision Support for EPG Adaptation Working Group for CPG for ‘Management of diagnosis and treatment of functional constipation in infant and children. Chairperson: Dr. suzan samer gad
|
PHASE |
MODULE |
STEP |
TOOL |
DECISION |
REASON (if not utilized) |
||||
|
Utilized |
Not utilized |
||||||||
|
ONE: SET-UP |
1.1. Preparation |
1 |
1 |
√ |
|
|
|||
|
2 |
√ |
|
|
||||||
|
2 |
|
√ |
|
|
|||||
|
3 |
|
√ |
|
|
|||||
|
4 |
|
√ |
|
|
|||||
|
5 |
3 |
√ |
|
|
|||||
|
4 |
√ |
|
|
||||||
|
1 |
√ |
|
|
||||||
|
6 |
5 |
√ |
|
|
|||||
|
|
|||||||||
|
TWO: ADAPTATION |
2.1. Scope and Purpose |
7 |
6 |
√ |
|
|
|||
|
2.2. Search and Screen |
8 |
2 |
√ |
|
|
||||
|
7 |
√ |
|
|
||||||
|
9 |
8 |
√ |
|
|
|||||
|
10 |
9 |
|
√ |
Decided to rely on inclusion/ exclusion criteria (filters) & PIPOH compatibility |
|||||
|
10 |
√ |
||||||||
|
2.3. Assessment |
11 |
9 |
√ |
|
|
||||
|
10 |
√ |
|
|
||||||
|
12 |
11 |
√ |
|
|
|||||
|
13 |
12 |
|
√ |
Decided to select NICU (Rs) of the XXXXXXXXXXXXXXXXXXXXXXXXXXXXX CPG |
|||||
|
14 |
13 |
|
√ |
Decided to rely on D3 Scores of AGREE II |
|||||
|
14 |
|
√ |
|||||||
|
15 |
15 |
|
√ |
Decided to rely on D5, D2 Scores of AGREE II |
|||||
|
2.4. Decision and Selection |
16 |
Table |
√ |
|
|
||||
|
17 |
Decision making and selection |
√ |
|
|
|||||
|
|
2.5. Customization |
18 |
16 |
√ |
|
|
|||
|
|
|||||||||
|
THREE: FINALIZATION |
3.1. External Review and Acknowledgment Module |
19 |
17 |
√ |
|
|
|||
|
20 |
|
√ |
|
|
|||||
|
21 |
|
√ |
|
|
|||||
|
22 |
|
√ |
|
|
|||||
|
3.2. Aftercare Planning |
23 |
18 |
√ |
|
|
||||
|
3.3. Final Production |
24 |
|
√ |
|
|
||||
Appendix Table 4. The RIGHT-Ad@pt checklist |
|||||
|
7 sections, 27 topics, and 34 items |
Assessment |
Page(s)* |
Note(s) |
||
|
BASIC INFORMATION |
|||||
|
Title/subtitle |
|||||
|
1 |
Identify the report as an adaptation of practice guideline(s), that is include "guideline adaptation", "adapting", "adapted guideline/recommendation(s)", or similar terminology in the title/subtitle. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
2 |
Describe the topic/focus/scope of the adapted guideline. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Cover/first page |
|||||
|
3 |
Report the respective dates of publication and the literature search of the adapted guideline. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
4 |
Describe the developer and country/region of the adapted guideline. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Executive summary/abstract |
|||||
|
5 |
Provide a summary of the recommendations contained in the adapted guideline. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Abbreviations and acronyms |
|||||
|
6 |
Define key terms and provide a list of abbreviations and acronyms (if applicable). |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Contact information of the guideline adaptation group |
|||||
|
7 |
Report the contact information of the developer of the adapted guideline. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
SCOPE |
|||||
|
Source guideline(s) |
|||||
|
8 |
Report the name and year of publication of the source guideline(s), provide the citation(s), and whether source authors were contacted. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Brief description of the health problem(s) |
|||||
|
9 |
Provide the basic epidemiological information about the problem (including the associated burden), health systems relevant issues, and note any relevant differences compared to the source guideline(s).
|
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Aim(s) and specific objectives |
|||||
|
10 |
Describe the aim(s) of the adapted guideline and specific objectives, and note any relevant differences compared to the source guideline(s). |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Target population(s) |
|||||
|
11 |
Describe the target population(s) and subgroup(s) (if applicable) to which the recommendation(s) is addressed in the adapted guideline, and note any relevant differences compared to the source guideline(s). |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
End-users and settings |
|||||
|
12 |
Describe the intended target users of the adapted guideline, and note any relevant differences compared to the source guideline(s). |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
13 |
Describe the setting(s) for which the adapted guideline is intended, and note any relevant differences compared to the source guideline(s). |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
RIGOR OF DEVELOPMENT |
|||||
|
Guideline adaptation group |
|||||
|
14 |
List all contributors to the guideline adaptation process and describe their selection process and responsibilities. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Adaptation framework/methodology |
|||||
|
15 |
Report which framework or methodology was used in the guideline adaptation process. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Source guideline(s) |
|||||
|
16 |
Describe how the specific source guideline(s) was(were) selected. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Key questions |
|||||
|
17 |
State the key questions of the adapted guideline using a structured format, such as PICO (population, intervention, comparator, and outcome), or another format as appropriate. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
18 |
Describe how the key questions were developed/modified, and/or prioritized. |
☐ Yes ☒ No ☐ Unclear |
|
|
|
|
Source recommendation(s) |
|||||
|
19 |
Describe how the recommendation(s) from the source guideline(s) was(were) assessed with respect to the evidence considered for the different criteria, the judgements and considerations made by the original panel. |
☐ Yes ☒ No ☐ Unclear |
|
|
|
|
Evidence synthesis |
|||||
|
20 |
Indicate whether the adapted recommendation(s) is/are based on existing evidence from the source guideline(s), and/or additional evidence. |
☐ Yes ☒ No ☐ Unclear |
|
|
|
|
21 |
If new research evidence was used, describe how it was identified and assessed. |
☐ Yes ☒ No ☐ Unclear |
NA |
|
|
|
Assessment of the certainty of the body of evidence and strength of recommendation |
|||||
|
22 |
Describe the approach used to assess the certainty/quality of the body/ies of evidence and the strength of recommendations in the adapted guideline and note any differences (if applicable) compared to the source guideline(s). |
☐ Yes ☒ No ☐ Unclear |
NA |
|
|
|
Decision-making processes |
|||||
|
23 |
Describe the processes used by the guideline adaptation group to make decisions, particularly the formulation of recommendations.
|
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
RECOMMENDATIONS |
|||||
|
Recommendations |
|||||
|
24 |
Report recommendations and indicate whether they were adapted, adopted, or de novo. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
25 |
Indicate the direction and strength of the recommendations and the certainty/quality of the supporting evidence and note any differences compared to the source recommendations(s) (if applicable). |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
26 |
Present separate recommendations for important subgroups if the evidence suggests important differences in factors influencing recommendations and note any differences compared to the source recommendations(s) (If applicable). |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Rationale/explanation for recommendations |
|||||
|
27 |
Describe the criteria/factors that were considered to formulate the recommendations or note any relevant differences compared to the source guideline(s) (if applicable). |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
EXTERNAL REVIEW AND QUALITY ASSURANCE |
|||||
|
External review |
|||||
|
28 |
Indicate whether the adapted guideline underwent an independent external review. If yes, describe the process. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Organizational approval |
|||||
|
29 |
Indicate whether the adapted guideline obtained organizational approval. If yes, describe the process. |
☒ Yes ☐ No ☐ Unclear |
SNS & NEBMC |
|
|
|
FUNDING, DECLARATION, AND MANAGEMENT OF INTEREST |
|||||
|
Funding source(s) and funder role(s) |
|||||
|
30 |
Report all sources of funding for the adapted guideline and source guideline(s), and the role of the funders. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Declaration and management of interests |
|||||
|
31 |
Report all conflicts of interest of the adapted and the source guideline(s) panels, and how they were evaluated and managed. |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
OTHER INFORMATION |
|||||
|
Implementation |
|||||
|
32 |
Describe the potential barriers and strategies for implementing the recommendations (if applicable). |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Update |
|||||
|
33 |
Briefly describe the strategy for updating the adapted guideline (if applicable). |
☒ Yes ☐ No ☐ Unclear |
|
|
|
|
Limitations and suggestions for further research |
|||||
|
34 |
Describe the challenges of the adaptation process, the limitations of the evidence, and provide suggestions for future research. |
☐ Yes ☒ No ☐ Unclear |
-- |
|
|